Myelomonocytic leukaemia following cyclophosphamide therapy of rheumatoid disease

Ann Rheum Dis. 1975 Dec;34(6):534-5. doi: 10.1136/ard.34.6.534.

Abstract

A 69-year-old woman treated for 31 months with daily oral cyclophosphamide for refractory rheumatoid disease developed acute myelomonocytic leukemia 21/2 years after stopping the drug. The possibility of a casual association between the therapy and subsequent leukaemia is supported by the growing experience with cytotoxic agents.

Publication types

  • Case Reports

MeSH terms

  • Arthritis, Rheumatoid / complications
  • Arthritis, Rheumatoid / drug therapy*
  • Cyclophosphamide / adverse effects*
  • Cyclophosphamide / therapeutic use
  • Female
  • Immunosuppression Therapy / adverse effects
  • Leukemia, Myeloid / etiology*
  • Leukemia, Myeloid / immunology

Substances

  • Cyclophosphamide